Fig. 1 Effects of protein phosphatase 2A–activating drug and protein phosphatase 2A–inhibiting drug in chronic myeloid leukemia. Effects of protein phosphatase.

Slides:

Advertisements

Similar presentations

Luis A. Carvajal, Ulrich Steidl Cell Stem Cell

Advertisements

Three different types of transfer functions with a codomain of [0,1].

Fig. 5 ALRN-6924 shows robust antileukemic activity in primary AML cells and in vivo. ALRN-6924 shows robust antileukemic activity in primary AML cells.

Fig. 1 LB100 and LB102 specifically inhibit PP2A phosphatase activity and the growth of BCR-ABL+ cells. LB100 and LB102 specifically inhibit PP2A phosphatase.

Human cells produce type I and III IFNs upon Af stimulation.

Fig. 7 Correlation of NHP and human ISGs.

Definition of the cellular source of IL-22.

Fig. 5 Putative latency-reversing agents exert differential effects on the different blocks to HIV transcription. Putative latency-reversing agents exert.

Differentiation of AZD4785 from MAPK pathway inhibitors in vitro

BAP1 deficiency results in thymic atrophy and loss of thymocyte populations. BAP1 deficiency results in thymic atrophy and loss of thymocyte populations.

Deubiquitinating activity, but not HCF-1 binding, is required for BAP1 function in thymocytes. Deubiquitinating activity, but not HCF-1 binding, is required.

Fig. 5 Hypoxic tumors from obese mice associate with increased production of IL-6 by adipocytes and myeloid cells. Hypoxic tumors from obese mice associate.

Fig. 1. Generation of the ΔEx50 mouse model.

Fig. 2 Whisker deprivation accelerates and enhances behavioral recovery after right S1FP photothrombosis. Whisker deprivation accelerates and enhances.

Cell viability tests. Cell viability tests. SEM images of (A) MC3T3-E1 cells and (B) MSCs on days 1, 3, and 5 of culture. (C) Survival rates of MC3T3-E1.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Fig. 3 Projected gains in MCP.

Fig. 4. The effect of combined inhibition of BCL-2 and BCR-ABL on leukemia LT-HSC frequency. The effect of combined inhibition of BCL-2 and BCR-ABL on.

Fig. 2 Preserved long-term functionality of the TEHVs over 1-year follow-up as assessed by ICE and cardiac MRI flow measurements. Preserved long-term functionality.

Microrobots with different cell-carrying capacities under different grid lengths (lg) and burr lengths (lb). Microrobots with different cell-carrying capacities.

In vivo release of doxycycline hyclate from the GRS in a swine model

Fig. 1 AVPR1A is regulated by the AR coactivator VAV3 and AR-V7 and is increased in advanced human PC. AVPR1A is regulated by the AR coactivator VAV3 and.

Fig. 1 Examples of experimental stimuli and behavioral performance.

Fig. 3 Scan rate effects on the layer edge current.

Reversal of diabetes-induced depletion of bone marrow (BM)–resident LSK cells and impairment of proliferation by ANG-(1-7) treatment. Reversal of diabetes-induced.

Fig. 1 Product lifetime distributions for the eight industrial use sectors plotted as log-normal probability distribution functions (PDF). Product lifetime.

Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.

Loss of BAP1 blocks T cell differentiation at the DN3 stage in vitro.

Fig. 3. Increased expression of exhaustion markers and apoptosis markers on CAR8 cells in the presence of TCR antigen. Increased expression of exhaustion.

Fig. 1. CAR4 and CAR8 cells demonstrate in vitro and in vivo antileukemic efficacy. CAR4 and CAR8 cells demonstrate in vitro and in vivo antileukemic efficacy.

Fig. 1 BMS binds to the pseudokinase domain of TYK2 and inhibits receptor-mediated TYK2 activation and downstream phosphorylation events in human.

Fig. 4 Rational therapeutic modulation of the tumor microenvironment sensitizes tumors to ICB. Rational therapeutic modulation of the tumor microenvironment.

Fig. 3 BMS blocks functional responses in primary immune cells driven by IL-23 and IL-12. BMS blocks functional responses in primary immune.

Fig. 1. DEL-1 is expressed by human and mouse osteoclasts.

BMS blocks functional responses in primary immune cells driven by IFNα

Fig. 6 SNP rs is a functional SNP in 22Rv1 cells.

Ror2-mediated signals are required for bone-resorbing activity of osteoclasts. Ror2-mediated signals are required for bone-resorbing activity of osteoclasts.

Fig. 3 Identification of KEECs that increase KCC2 expression in human RTT neurons. Identification of KEECs that increase KCC2 expression in human RTT neurons.

Fig. 1 Distribution of total and fake news shares.

In vitro cell-release experiments on a glass substrate.

Fig. 6 RUNX/CBFB interaction inhibitor, Ro5-3335, significantly decreases mouse neurofibroma growth in vivo. RUNX/CBFB interaction inhibitor, Ro5-3335,

Fig. 1 Caspase-8 and -9 are both activated during intrinsic and extrinsic apoptosis. Caspase-8 and -9 are both activated during intrinsic and extrinsic.

Type I and III IFNR expression on hematopoietic cells is required for protection against IA. Type I and III IFNR expression on hematopoietic cells is required.

Fig. 3 Proteomic analysis and Western blot analysis of protein cargos of various EVs. Proteomic analysis and Western blot analysis of protein cargos of.

Protein expression profile in a dasatinib-resistant cell line.

Attacking Cancer at Its Root

Fig. 3 Local Maraba treatment of TNBC tumors provides long-term systemic protection. Local Maraba treatment of TNBC tumors provides long-term systemic.

by Samuel J. Taylor, Johanna M. Duyvestyn, Samantha A. Dagger, Emma J

Fig. 4. Paclitaxel promotes the expression of invasive isoforms of MENA in the primary breast cancer microenvironment. Paclitaxel promotes the expression.

Representative CT and PET/CT images of three patients with NSCLCs

PD and efficacy of AZD4785 in KRAS mutant lung cancer xenograft models

Fig. 1 Crohn’s disease association within the LRRK2 locus.

Fig. 5. Vascularization of human liver seed grafts.

Fig. 5 Comparison of the liquid products generated from photocatalytic CO2 reduction reactions (CO2RR) and CO reduction reactions (CORR) on two catalysts.

Fig. 6 Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9 in vivo. Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9.

Fig. 6 Schematic representation of EMT during the metastatic cascade.

Bio-AMS enhances the activity of rifampicin and ethambutol in vitro

Fig. 4 Map of δ18OVSMOW in groundwaters of the British Isles (left) and Strontium (87Sr/86Sr) biosphere map of Great Britain (right). Map of δ18OVSMOW.

Fig. 2 Increasing KLF17, CDH1, and LASS2 expression reduced malignant progression and promoted apoptosis of tumor cells. Increasing KLF17, CDH1, and LASS2.

Fig. 5. High burdens of AA signature mutations and predicted immunogenicity in Taiwan HCCs. High burdens of AA signature mutations and predicted immunogenicity.

Effects of highly concentrated SFN provided as BSE in T2D patients

Fig. 7 BEL immune response.

Fig. 2. Mechanism of PD-L1 down-regulation in NOD HSPCs.

Fig. 3 Superiority of BAFF-R versus CD19-CAR T cells in a Burkitt lymphoma model is not due to greater tumor antigen density. Superiority of BAFF-R versus.

Fig. 4 Gallium increases P. aeruginosa sensitivity to peroxides.

Fig. 1 Generation and characterization of MeV-based vaccine candidates for Lassa virus. Generation and characterization of MeV-based vaccine candidates.

Fig. 2 Daily TNC pickups and drop-offs for an average Wednesday in fall 2016 (1). Daily TNC pickups and drop-offs for an average Wednesday in fall 2016.

Fig. 3 Gene expression analysis in 48-plex drug treatment experiments.

PD and efficacy of AZD4785 in a KRAS wild-type lung cancer PDX model

Fig. 5 CD19-tPSMA(N9del) CAR T cell numbers in mouse and human.

Presentation transcript:

Fig. 1 Effects of protein phosphatase 2A–activating drug and protein phosphatase 2A–inhibiting drug in chronic myeloid leukemia. Effects of protein phosphatase 2A–activating drug and protein phosphatase 2A–inhibiting drug in chronic myeloid leukemia. (A) Hematopoietic stem cell (HSC) and progenitor activity after protein phosphatase 2A–activating drug (PAD) or protein phosphatase 2A–inhibiting drug (PID) treatment. (1) Eight PADs were independently tested in nine laboratories. (2) Average of data from Perrotti group’s publications. (3) PAD-induced apoptosis also in BCR-ABL1T315I chronic myeloid leukemia (CML). (4) PID values are from Lai et al. (1). (5) FTY720 and derivatives increase bone marrow (BM) homing of normal but not tumor HSCs. (B) Effects of LB100 on CML cell proliferation and survival. Data are from figures 6 and 8 and figure S8 of Lai et al. (1). TKI, tyrosine kinase inhibitor; CFC, colony-forming cell; LTC-IC, long-term culture-initiating cell; NR, nonresponder; N/A, not applicable; N.S, nonsignificant differences; wk, weeks; DAS, dasatinib; RT-PCR, reverse transcription polymerase chain reaction. NBM, normal bone marrow; CFSEmax, maximum staining with carboxyfluorescein succinimidyl ester; hLSC, human leukemia stem cell; CMPs, common myeloid progenitors; LSK, lineage-negative Sca+ Kit+; DA, dasatinib. Danilo Perrotti et al., Sci Transl Med 2019;11:eaau0416 Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works